期刊文献+

腺苷蛋氨酸联合还原型谷胱甘肽治疗药物性肝损伤患者疗效研究 被引量:6

Clinical efficacy of adenosylmethionine and reduced glutathione in treating patients with drug-induced liver injury
下载PDF
导出
摘要 目的探讨应用腺苷蛋氨酸与还原型谷胱甘肽联合治疗药物性肝损伤(DILI)患者的疗效。方法2017年10月~2020年10月我院收治的90例DILI患者,被随机分为对照组45例和观察组组45例,分别给予还原型谷胱甘肽或还原型谷胱甘肽联合腺苷蛋氨酸治疗。常规检测血清丙二醛(MDA)、超氧化物岐化酶(SOD)和谷胱甘肽过氧化物酶(GSH-Px)。结果本组患者治疗2~6(3.1±1.4)w,观察组血清ALT、AST和TBIL水平分别为(61.2±8.3)U/L、(54.5±7.4)U/L和(14.4±4.1)μmol/L,显著低于对照组【分别为(86.5±11.5)U/L、(63.1±8.0)U/L和(21.5±5.4)μmol/L,P<0.05】;血清前白蛋白和胆碱酯酶水平分别为(205.5±1.9)mg/L和(5224.1±589.9)u/L,显著高于对照组【分别为(188.5±34.2)mg/L和(4933.9±602.2)u/L,均P<0.05】,而血清总胆汁酸水平为(7.1±1.7)μmol/L,显著低于对照组【(9.5±2.1)μmol/L,P<0.05】;血清丙二醛水平为(4.5±0.7)μmol/L,显著低于对照组【(6.5±0.9)μmol/L,P<0.05】,而血清超氧化物岐化酶和谷胱甘肽过氧化物酶分别为(83.1±7.9)U/L和(125.1±13.7)u/L,显著高于对照组【(75.9±7.2)U/L和(105.5±11.1)u/L,P<0.05】。结论联合应用腺苷蛋氨酸与还原型谷胱甘肽治疗DILI患者近期效果较好,可有效抑制体内炎症反应,改善氧化应激状态和肝功能指标。 Objective The aim of this study was to observe the clinical efficacy of adenosylmethionine and reduced glutathione in treating patients with drug-induced liver injury(DILI).Methods 90 patients with DILI were enrolled in our hospital between October 2017 and October 2020,and were randomly divided into control and observation group,with 45 cases in each group.The patients in the control group was treated with reduced glutathione,while those in the observation group was additionally treated with adenosylmethionine at base of reduced glutathione.Serum malondialdehyde(MDA),superoxide dismutase(SOD)and glutathione peroxidase(GSH-Px)were routinely detected.Results After two to six(3.1±1.4)week treatment,serum ALT,AST and bilirubin levels in the observation group were(61.2±8.3)U/L,(54.5±7.4)U/L and(14.4±4.1)μmol/L,all significantly lower than[(86.5±11.5)U/L,(63.1±8.0)U/L and(21.5±5.4)μmol/L,respectively,P<0.05]in the control;serum prealbumin and cholinesterase levels were(205.5±1.9)mg/L and(5224.1±589.9)u/L,both significantly higher than[(188.5±34.2)mg/L and(4933.9±602.2)u/L,respectively,P<0.05],while serum total bile acids was(7.1±1.7)μmol/L,significantly lower than[(9.5±2.1)μmol/L,P<0.05]in the control;serum MDA level was(4.5±0.7)μmol/L,significantly lower than[(6.5±0.9)μmol/L,P<0.05],while serum SOD and GSH-Px levels were(83.1±7.9)U/L and(125.1±13.7)u/L,both significantly higher than[(75.9±7.2)U/L and(105.5±11.1)u/L,respectively,P<0.05]in the control group.Conclusion The short-term clinical efficacy of adenosylmethionine and reduced glutathione combination in treatment of patients with DILI is good,which could effectively inhibit inflammatory reactions and oxidative stress,and protect the liver functions.
作者 肖露 胡弦 蔡颖珂 梅凡 Xiao Lu;Hu Xian;Cai Yingke(Department of Thoracic Surgery,Union Jiangbei Hospital,Wuhan 430000,Hubei Province,China)
出处 《实用肝脏病杂志》 CAS 2022年第1期66-69,共4页 Journal of Practical Hepatology
基金 武汉市科技局科研基金资助项目(编号:20191210)
关键词 药物性肝损伤 腺苷蛋氨酸 还原型谷胱甘肽 治疗 Drug-induced liver injury Adenosylmethionine Reduced glutathione Therapy
  • 相关文献

参考文献7

二级参考文献67

  • 1许建明.急性药物性肝损伤诊治建议(草案)[J].中华消化杂志,2007,27(11):765-767. 被引量:349
  • 2Bjornsson ES, Bergmann OM, Bjomsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425. 被引量:1
  • 3Fontana RJ, Watkins PB, Bonkovsk-y HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct[J]. Drug Saf, 2009, 32(1): 55-68. 被引量:1
  • 4Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug- induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966. 被引量:1
  • 5Li L, Jiang W, Wang J. Clinical analysis of 275 cases of acute drug- induced liver disease[J]. Front Med China, 2007, 1(1): 58-61. 被引量:1
  • 6Hoofnagle JH, Serrano J, Knoben JE, et al. LiverTox: a website on drug-induced liver injury[J]. Hepatology, 2013, 57(3): 873-874. 被引量:1
  • 7Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver[J]. Semin Liver Di, 2002, 22(2): 145-155. 被引量:1
  • 8Bjomsson ES. Epidemiology and risk factors for idiosyncratic drug- induced liver injury[J]. Semin Liver Dis, 2014, 34(2): 115-122. 被引量:1
  • 9Hou FQ, Zeng Z, Wang GQ. Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes[J]. Cell Biochem Biophys, 2012, 64(2): 77-83. 被引量:1
  • 10Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry[J]. Hepatology, 2006, 44(6): 1581-1588. 被引量:1

共引文献434

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部